Lipoprotein (a) in a population-based study: More significant in Turkish women than men?;Popülasyona dayali bir çalişmada lipoprotein (a): Klinik önemi kadinlarimizda daha mi fazla?

Anadolu Kardiyoloji Dergisi

Volumn 5, Issue 4, 2005, Pages 271-277

  Onat, Altan ^a   Yazici, Mehmet ^b   Hergenç, Gülay ^c   Doǧan, Yüksel ^d   Karabulut, Ahmet ^e   Sari, Ibrahim ^e   Türkmen, Serdar ^f   Can, Günay ^g   Sansoy, Vedat ^h  

^a Turkish Society of Cardiology   (Turkey)

^b Üniversitesi Izzet Baysal Tip Fakültesi   (Turkey)

^c YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^d Acibadem Bakirköy Hastanesi Kardiyoloji Bölümü   (Turkey)

^e DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f GAZIANTEP UNIVERSITY   (Turkey)

^g ISTANBUL UNIVERSITY   (Turkey)

^h ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coronary heart disease; Lipoprotein(a); Metabolic syndrome; Population based study; Turkish adults

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; FEMALE; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; LINEAR REGRESSION ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEPHELOMETRY; OBESITY; SMOKING; SYSTOLIC BLOOD PRESSURE; TURKEY (REPUBLIC);

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; ISOMERISM; LINEAR MODELS; LIPOPROTEIN(A); MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; ODDS RATIO; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; TURKEY;

EID: 29544446043     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. McLean J, Tomlinson J, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
2. Marcovina SM, Hegele RA, Koschinsky ML. Lipoprotein(a) and coronary heart disease. Curr Cardiol Rep 1999; 1: 105-11.
3. Danesh J, Collins R, Peto R. Lipoprotein a and coronary heart disease: a meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
4. Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98: 2980-7.
5. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003; 10: 63-71.
6. Mahley RW, Palaoǧlu KE, Atak Z, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36: 839-59.
7. Hergenç G, Özsüllü T, Çetinalp P, Beşoluk Ş, Sönmez B. Lp(a) levels in men with coronary artery occlusion and healthy male controls. Biochem Soc Trans 1999; 27: A1222.
8. Adam B, Talu C, Bedir A, Alvur M, Sagkan O. The levels of lipids, lipoproteins and apolipoproteins in healthy people in the central region of the Black Sea. Jpn Heart J 1999; 40: 427-34.
9. Öbrem A, Deǧer O, Kulan K, et al. Evaluation of lipoprotein(a) [Lp(a)] as a risk factor for coronary artery disease in the Turkish population. Clin Biochem 1995; 28: 171-3.
10. Onat A, Uyarel H, Hergenç G, ve ark. Yüksek riskli bir örneklemimizde lipoprotein(a): Daǧilimi ve baǧintilari zemininde Türk erkeklerinde insülinemi ile ters ilişkisi gözlemi. Türk Kardiyol Dern Arş 2004; 32: 82-90.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-509.
12. Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. 2nd ed. Geneva: WHO; 1982.
13. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10.
14. Executive Summary of the third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
15. American Diabetes Association: Clinical practice recommendations. Diabetes Care 1997; 20(Suppl): S1-S70.
16. Chien KL, Lee YT, Sung FC, et al. Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors. Atherosclerosis 1999; 143: 267-73.
17. Grover GJ, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol and lipoprotein(a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 2003; 100: 10067-72.
18. Rainwater DL, Haffner SM: Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998; 18: 1335-41.
19. Craig WY, Neveux LM, Palomaki GE, Clevelang MM, Haddow JE. Lipoprotein (a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 11: 2301-6.
20. Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997;96: 1390-7.
21. Onat A. Lipids, lipoproteins, and apolipoproteins among Turks, and impact on coronary heart disease. Anadolu Kardiyol Derg 2004; 4: 236-45.
22. Onat A, Ceyhan K, Başar Ö, et al. Metabolic syndrome: major impact on coronary risk in a population with low choleterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-92.
23. Glader CA, Birgander LS, Stenlund H, Dahlen GH. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002; 252: 27-35.
24. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995; 274:1771-4.
25. Luc G, Bard JM, Arveiler D, et al. PRIME Study Group: Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis. 2002; 163: 377-84.
26. Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31: 519-25.
27. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-9.
28. Rifai N, Ma J, Sacks FM, Ridker PM, et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem 2004; 50:1364-71.